Table of contents
February 2003 Vol 3 No 2
In this issue
p79 | doi:10.1038/nrc997
Research Highlights
Apoptosis: Cheating death
p81 | doi:10.1038/nrc1009
Therapeutics: Mass destruction
p82 | doi:10.1038/nrc1004
Prognosis: Prediction power
p82 | doi:10.1038/nrc1006
Carcinogenesis: Double whammy
p83 | doi:10.1038/nrc1000
In the news
Out-of-body experience
p84 | doi:10.1038/nrc1002
Telomere maintenance: The road less travelled
p84 | doi:10.1038/nrc1008
Tumour suppressors: A greater loss
p85 | doi:10.1038/nrc1005
Trial Watch
Prostate-cancer-specific oncolytic virus | Antisense for pancreatic cancer
p85 | doi:10.1038/nrc998
Epigenetics: Breaking the silence
p86 | doi:10.1038/nrc1001
Epigenetics: Gender-dependent tumour suppression
p86 | doi:10.1038/nrc1007
News in Brief
Technology | Oncogenes | Therapeutics | Chemoprevention
p87 | doi:10.1038/nrc1003
Tumorigenesis: Translating cancer
p87 | doi:10.1038/nrc999
Reviews
Disruption of differentiation in human cancer: AML shows the way
Daniel G. Tenen
p89 | doi:10.1038/nrc989
Inhibiting the p53–MDM2 interaction: an important target for cancer therapy
Patrick Chène
p102 | doi:10.1038/nrc991
The endothelin axis: emerging role in cancer
Joel Nelson, Anna Bagnato, Bruno Battistini & Perry Nisen
p110 | doi:10.1038/nrc990
The role of p53 in determining sensitivity to radiotherapy
Andrei V. Gudkov & Elena A. Komarova
p117 | doi:10.1038/nrc992
Coordinated regulation of life and death by RB
B. Nelson Chau & Jean Y.J. Wang
p130 | doi:10.1038/nrc993
Perspective
Opinion
An analysis of cancer research funding in the UK
Liam O'Toole, Paul Nurse & George Radda
p139 | doi:10.1038/nrc994

